Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05712889 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
A Phase 1 study, sponsored by Vincerx Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT05712889: Completed Phase 1 study, sponsored by Vincerx Pharma.
NCT05712889 is a Phase 1 study that has completed, run by Vincerx Pharma. The registered enrollment target is 29 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05712889, a Phase 1 study, has completed, sponsored by Vincerx Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
Determine the safety, tolerability, and maximum tolerated dose (MTD) of IV administered VIP236 as monotherapy in patients with advanced solid tumor cancer
Interventions
- DRUG VIP236 (Q3W)
- DRUG VIP236 (Q2W)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2023-01-24 |
| Est. Completion | 2024-10-10 |
| Phase | Phase 1 |
What the finished NCT05712889 record still lists
NCT05712889 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% lower).
The record links to 0 conditions, and to 2 interventions - of which VIP236 (Q3W) is the first listed.
NCT05712889 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05712889 about?
NCT05712889 is a clinical study titled "Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer". Determine the safety, tolerability, and maximum tolerated dose (MTD) of IV administered VIP236 as monotherapy in patients with advanced solid tumor cancer
What is the current status of trial NCT05712889?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2023-01-24. Estimated completion is 2024-10-10.
What interventions are being tested in trial NCT05712889?
The interventions under investigation include: VIP236 (Q3W) (DRUG), VIP236 (Q2W) (DRUG).
Who is sponsoring clinical trial NCT05712889?
This trial is sponsored by Vincerx Pharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05712889's enrollment target sits among peer trials
29 1440th of 2000 higher than 554 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI